134 results about "Movement disorders" patented technology

The invention discloses a construction method of a dyskinesia phenotype classification model of a Parkinson's disease patient and a diagnosis system, and belongs to the field of medical auxiliary diagnosis devices. The system comprises an image acquisition module and a phenotype classification module, wherein the classification module is composed of a space-time diagram convolution feature extraction module, a hierarchical node fusion module, a functional brain network construction and feature extraction module, a local brain region feature screening module, a hierarchical brain feature pairing fusion module and an output module. According to the method, multi-modal brain image data are fused, space-time and complex relation characteristics of a brain region are deeply mined, a key lesion brain region is positioned, and dyskinesia phenotypes are accurately classified by training a neural network. The system can significantly improve the diagnosis accuracy of the Parkinson's disease dyskinesia phenotype, has good expansibility and adaptability, and provides a scientific basis for early diagnosis and personalized intervention. The invention further relates to an operation method of the system, an auxiliary diagnosis device and a computer readable storage medium.

Systems and methods for providing recommended doses and instructions for pharmaceutical treatments, and more particularly systems and methods for measuring physiological and / or electrophysiological signals from a subject and providing recommended doses and instructions of pharmaceuticals based at least in part on the measured signals are described. Further, the recommended doses and instructions are based at least in part on a subject's disease(s), disorder(s), or injuries and / or symptom(s) of such, and / or side effects of medications or treatments the subject is receiving. The recommended doses and instructions are personally tailored to the subject to precisely and personally address the subject's needs, and may be based in part on correlation with database(s) comprising historical data of the subject and / or other subjects to treat the subject's movement disorders, injuries to the body or brain, cognitive diseases and disorders, sleep diseases and disorders, chronic pain, or other conditions.

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The invention discloses a weight loss gait test evaluation and training device and method, and the device comprises a weight loss control module which is used for weighing the weight of a user in real time and automatically adjusting the air pressure of an air bag according to a set weight loss proportion; the gait information acquisition module is used for synchronously acquiring plantar pressure distribution, lower limb joint kinematics parameters and double-view video data; the multi-modal gait evaluation grading model module is used for processing plantar pressure distribution, lower limb joint kinematics parameters and double-view video data and outputting lower limb dyskinesia grades; and the training scheme generation model module is used for automatically generating a training scheme including a weight reduction proportion, a treadmill speed, single exercise time and training times per week according to the lower limb dyskinesia level and the personal information of the user.

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.

To provide a motion analysis device that can be used for evaluating a motor function or motion disorder.SOLUTION: A motion analysis device (20) includes elbow flexure ratio calculation means (222) for calculating an elbow flexure ratio of an upper limb in elevation exercise which is expressed by an expression (1) or an expression (2) from respective three-dimensional coordinate data of the shoulder, elbow, and hand of a person to be evaluated when the person to be evaluated is in upper limb elevation exercise. In the expression (2), SH represents a vector from the shoulder to the hand, SE represents a vector from the shoulder to the elbow, and EH represents a vector from the elbow to the hand.SELECTED DRAWING: Figure 1

In an embodiment, a method of reducing movement disorder symptom severity of a patient is presented. A method may include securing a wearable device to a body part of a patient through an attachment system. A method may include activating a mechanical transducer of a wearable device to provide a vibratory output to one or more nerves in a vicinity of a wrist of the patient. A vibratory output may have a vibrational strength of about 0.30 Grms to about 0.78 Grms.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The invention relates to the technical field of medicines, and discloses six adeno-associated virus (AAV) injections carrying novel artificial chemical genetics receptor gene sequences, and a combinatorial chemical genetics scheme formed by the injections and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

The invention relates to the technical field of sheep monitoring, in particular to a method for monitoring the health state of sheep through gait recognition, which comprises the following steps: acquiring a sheep walking video stream through a camera, reconstructing and generating a three-dimensional skeleton motion sequence based on a skeleton motion track, and marking space-time coordinates of hip joint, knee joint and hoof key points; according to the three-dimensional skeleton motion sequence, the knee joint buckling angular velocity peak value, the same-side front and rear hoof grounding time difference and the trunk lateral swing amplitude in a single-step period are calculated, and a gait space-time coordination parameter set is constructed; and inputting the gait time-space coordination parameter set into a disease decoupling model based on anti-factual reasoning, and outputting an early arthritis risk index and a neurological dyskinesia probability. According to the invention, the arthritis risk index and the neurological dyskinesia probability are calculated, early recognition and risk grading early warning of dyskinesia are realized, and the intelligent level and the response capability of a health monitoring system are remarkably improved.

The invention provides a Parkinson's disease detection method and system based on plantar pressure diagram modeling. The method comprises the following steps: S1, dividing an original plantar pressure signal into a time slice sequence with a fixed length; step S2, converting each time slice in the time slice sequence into a plantar pressure diagram, step S3, inputting the plantar pressure diagram into a multi-level residual image convolutional network to perform multi-order spatial feature extraction, and outputting multi-scale spatial features; s4, splicing the output multi-scale spatial features into a time sequence according to a time sequence, inputting the time sequence into a Transform encoder, and outputting global time sequence features; and S5, based on the global time sequence features, outputting a Parkinson disease recognition result. According to the method, the detection efficiency can be effectively improved, subjective factor interference is reduced, the model generalization ability is enhanced, and reliable technical support is provided for objective detection of dyskinesia diseases such as Parkinson's disease.

Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The invention discloses an exoskeleton robot rehabilitation parameter dynamic evaluation method and system based on gait quantitative analysis, and the method achieves the precise matching of a closest reference standard for a patient through an intelligent reference matching algorithm based on the dynamic reference matching technology of height and weight, and achieves the personalized adaptation of an evaluation reference. Misjudgment caused by an evaluation mode only depending on doctor experience is avoided, rehabilitation training parameters better fit actual physiological features of a patient, meanwhile, through a multi-dimensional gait scoring model, angle deviation analysis and bilateral coordination evaluation are fused, left and right joint activities are paired and defined, and a bilateral limb activity difference value is calculated, so that the rehabilitation training accuracy is improved. The asymmetric dyskinesia of a hemiplegic patient is accurately identified, a quantitative basis is provided for making a rehabilitation scheme, accurate judgment is performed according to own data characteristics of different users, and a rehabilitation treatment scheme is customized for the users by using quantitative data reference, so that the consistency and accuracy of the rehabilitation effect are ensured.

A method of treating a patient suffering from over-active bladder (OAB) or other urinary or bowel movement disorder includes placing at least one thermal device on an exterior portion of the patient's body proximate to the patient's saphenous nerve or the patient's tibial nerve. The thermal device includes a number of heating elements and a number of cooling elements arranged in a thermal array. The method also includes activating the heating elements and the cooling elements to stimulate the saphenous nerve and / or the tibial nerve to alleviate symptoms of the over-active bladder or the other urinary or bowel movement disorder.

The present disclosure provides pharmaceutical compositions comprising a cannabinoid, and dosage forms comprising same, for oral delivery, such as sublingual or buccal delivery. The compositions of the present disclosure are substantially homogeneous and remain stable and monophasic upon storage. Also provided are methods of using the compositions for pain management and to treat various diseases and conditions, including dementia, sleep disorders, movement disorders, mental disorders, and multiple sclerosis.

Disclosed are a dual regulator for mGluR5 and HDAC6 and use thereof. More specifically, disclosed are a compound that simultaneously regulates mGluR5 and HDAC6, and use thereof as a therapeutic agent for movement disorders.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

Disclosed examples relate to a system and method for creating and integrating self-supervised learning (SSL) digital movement biomarkers into electronic health records (EHRs) for enhanced diagnostic support and treatment monitoring, particularly for rare diseases and movement disorders. Example systems employ SSL techniques to analyze video data, tracking body key points and extracting kinematic data without the need for human-labeled annotations. Disclosed examples generate digital movement biomarker profiles that quantify symptoms and track disease progression, facilitating the objective measurement of drug impacts on symptoms. Example systems include components for video processing, compliance checking, pose estimation, context analysis, kinematic measurement, and classification. The digital movement biomarker profiles are stored securely and made accessible for clinical use, offering a novel approach to personalized medicine by enabling the identification of disorder-specific traits and symptom similarities across different disorders.

Treatments of neuromuscular conditions, activity-induced muscle damage, metabolic myopathies, and movement disorders with compositions comprising 2-((5-fluoropyridin-3-yl)methyl)-6-(2-(2,2,2-trifluoroethoxy)pyrimidin-5-yl)pyridazin-3(2H)-one (Compound 1), as well as solid forms of Compound 1, and pharmaceutical compositions of Compound 1, and kits of Compound 1, are described herein.

Devices, systems, and techniques for monitoring patient movements using remote sensors are described herein. For example, processing circuitry may be configured to control a user interface of a mobile computing device to deliver a notification to a user to perform at least one movement test and receive, via the user interface, user input requesting to begin the at least one movement test. Responsive to receiving the user input, the processing circuitry can control the user interface to display a set of instructions for the at least one movement test during a period of time, control a camera of the mobile computing device to generate image data of the patient corresponding to the at least one movement test during the period of time, and determine, based on the image data, one or more metrics corresponding to the at least one movement test.

To provide compositions and methods for treating and preventing cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, and addiction.SOLUTION: Also provided are methods for the diagnosis and monitoring of cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, addiction, and other conditions such as convulsion or seizure. These compositions comprise fatty acid compounds and salts thereof which may be administered either alone, in combination with other medicaments, or as part of various treatment regimens. The provided compositions are effective for modulating markers, including, but not limited to, behavior associated with cognitive impairment, movement disorders, chronic pain, depression, decreased appetite, opiate addiction, and other related conditions. Methods for administering the compositions are also provided.SELECTED DRAWING: Figure 1

The present invention belongs to the technical field of medical devices, and specifically relates to an anti-fall walking training device, which is mainly used to assist patients with limb movement disorders caused by various diseases such as spinal cord injury and stroke to perform rehabilitation training; it mainly includes: a frame, having a first connecting arm and a second connecting arm; a first moving part connected to the first connecting arm; a second moving part connected to the second connecting arm; a driving mechanism, including a shell located between the first moving part and the second moving part and connected to the first moving part and the second moving part; a driving part arranged in the shell; a transmission part connected to the driving part, and the transmission part rotates in the shell under the drive of the driving part; the transmission part can partially move in the direction of the first moving part and the second moving part to form a coupling relationship with the first moving part and the second moving part; when the coupling relationship is formed, the driving part drives the first moving part and the second moving part to move synchronously through the transmission part.

The invention belongs to the technical field of deep learning and medical image processing, and particularly relates to a method for identifying eyelid retraction and eyeball dyskinesia for TAO, which solves the technical problems in the background technology and comprises the following steps: acquiring facial appearance images of first eye positions and rotating eye positions of multiple patients; eye cutting is carried out on all the facial appearance images to obtain a first eye position data set and a rotating eye position data set, eyelid retraction and eyeball dyskinesia conditions of all the data are marked, and a drawing scale is recognized; a semantic segmentation model of the eye structures is constructed, semantic segmentation is achieved, and coordinates of all the eye structures are obtained; constructing an auxiliary recognition model, and recognizing eyelid retraction and eyeball dyskinesia of the eye structure in combination with a drawing scale; and training the semantic segmentation model, carrying out semantic segmentation on the eye picture, then carrying out quantitative identification on eyelid retraction and eyeball dyskinesia of the eye picture by using the auxiliary identification model, and outputting an auxiliary identification result.

A peripheral nerve stimulator to stimulate a peripheral nerve to treat essential tremor and other movement disorders, as well as overactive bladder, cardiac dysfunction and neurotransmitter dysfunction is provided. The peripheral nerve stimulator can be a noninvasive surface stimulator to provide multi-modal optimized therapy. Stimulation can be vibrational, electromechanical, thermal, radiant, electrical, magnetic, electromagnetic, light, mechanical, chemical, thermal, ultrasonic, radiofrequency (RF), acoustic, infrared, ultraviolet, x-ray, and / or microwave. Stimulation can be delivered using an open loop system and / or a closed loop system with feedback. Stimulation can be to one site or multiple sites.

The invention discloses a calcaneal fracture three-dimensional traction reduction device, and relates to the technical field of medical instruments, the calcaneal fracture three-dimensional traction reduction device comprises a base, a supporting pad is fixedly arranged at the top of the base, a side plate is fixedly arranged on the side wall of the supporting pad, and a horizontal plane moving mechanism is rotatably arranged at the top in the base. Through the arrangement of an arc plate, an arc block, a rotating seat and an arc limiting groove, a connecting rod and a rotating ring are driven to drive a calcaneal fracture part of a patient to rotate synchronously aiming at the rotation of the calf of the patient, so that the traction direction of the patient is always kept consistent, and the whole body is driven to move through the rotation of the calf during movement; the fracture traction part of a patient is prevented from being pulled and painful, small-range movement of the patient can be guaranteed, the comfort of the patient is improved, the traction puncture part of the patient can be prevented from being painful, synchronous adjustment of the traction force direction along with movement is guaranteed, and joint stiffness and movement disorder caused by long-time fixation of the joint are avoided.

The technical scheme of the invention discloses a brain-computer interface assisted patient gait training system. The brain-computer interface system is combined to provide the accuracy of the brain motion intention, the infrared optical motion capture system is adopted to capture reflective identification points on the human body through infrared rays emitted by the lens, and accurate and real-time motion information is collected and generated. The gait of a standing or walking training patient under the suspended sky rail is tracked and measured in real time, and the track of a three-dimensional space point, the motion posture of a rigid body and the action of a human body are recorded as real visual feedback of a lower limb training brain-computer interface of the dyskinesia patient. It is guaranteed that when the brain of a patient outputs a motion intention, input from the real motion ability of the patient can be obtained, peripheral electrical stimulation or epidural electrical stimulation is combined as tactile feedback, and therefore precise closed-loop regulation and control of the brain on the output of a motion control signal of the paralyzed lower limb are promoted.

The present invention relates to antisense oligonucleotides capable of modulating the expression of Tau in a target cell. The oligonucleotide lines hybridize to the MAPT mRNA. The present invention further relates to conjugates of the oligonucleotides, and pharmaceutical compositions and methods for the treatment of a Tau aberrant deposition lesion (Tauopathy), Alzheimer's disease (AD), frontotemporal dementia (FTD), FTDP-17, progressive ocular nuclear paralysis (PSP), chronic traumatic brain lesion (CTE), corticobasal nuclear degeneration (CBD), epilepsy, a Display syndrome, depression, a seizure disorder (disorder of epileptic seizure), and a movement disorder (disorder of movement).

Provided are isotopically-labelled Trapidil derivatives useful for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease. The isotopically-labelled Trapidil derivatives include deuterated Trapidil derivatives. Additionally provided are combination therapies of isotopically-labelled Trapidil derivatives and additional therapeutic agents for the treatment of Parkinson's disease and movement disorders associated with Parkinson's disease.

Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.

The present disclosure provides a crystalline form of enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating mood disorders, neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using a crystalline form of enantiopure deuterium-enriched bupropion.